Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.


TSXV:NRX - Post by User

NurExone Biologic Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(50)
•••
Post by cmarketinsightson Jan 03, 2025 5:34pm
75 Views
Post# 36386851

A New Frontier in Regenerative Medicine

A New Frontier in Regenerative MedicineA New Frontier in Regenerative Medicine

NurExone Biologic Inc. (TSXV: NRX) , an Israeli biotech company, is developing a novel exosome-based drug delivery platform aimed at treating central nervous system injuries, including spinal cord and optic nerve injuries. Their lead therapy, ExoPTEN, has already received orphan drug designation from both the FDA and EMA, highlighting its potential significance in addressing unmet medical needs.

With preclinical studies completed and plans for phase one trials by the end of 2025, the company is positioning itself in an emerging industry that currently has no FDA-approved exosome therapeutics. Could this innovative approach reshape the treatment landscape for conditions like acute spinal cord injury?

Read the full report here: https://www.researchfrc.com/content/reports/post/188/a-potential-breakthrough-in-spinal-cord-and-optic-nerve-injury-treatment
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities